ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
NYSE:ADCT
Price:
4.78 USD
-3.82%
Market Closed
Updated:
Apr 25, 2024
ADC Therapeutics SA
Cash Equivalents
Last
Value
3-Years CAGR
5-Years CAGR
|
ADC Therapeutics SA
Cash Equivalents Peer Comparison
Comparables:
ACIU
CRSP
BSLN
IDIA
KURN
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Cash Equivalents
$278.6m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Cash Equivalents
CHf78.5m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Cash Equivalents
CHf59.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-7%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is ADC Therapeutics SA's Cash Equivalents?
Cash Equivalents
278.6m
USD
278.6m
USD
Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Cash Equivalents amounts to 278.6m USD.
What is ADC Therapeutics SA's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
15%
15%
Over the last year, the Cash Equivalents growth was -15%. The average annual Cash Equivalents growth rates for ADC Therapeutics SA have been -14% over the past three years , 15% over the past five years .
You don't have any saved screeners yet
